Test measures immune response to improve ovarian cancer diagnosis

Test measures immune response to improve ovarian cancer diagnosis

Researchers have developed a simple blood test that measures the body’s own immune response to improve diagnosis of ovarian cancer.

Ovarian cancer is one of the most common gynaecologic cancers, with the highest mortality rate. About 300,000 new cases are diagnosed globally each year, with an estimated 60% of women dying within five years after diagnosis.

The new study found that testing for a specific immune biomarker allows clinicians to identify whether growths on the ovaries are cancerous or not, without the need for tests like MRI scans or ultrasounds.

The clinical trial was conducted in two hospitals in Melbourne, with the results published in Scientific Reports.

Senior Author and Chief Investigator, RMIT University’s Professor Magdalena Plebanski, said the test could be an important diagnostic tool for assessing suspicious ovarian growths before operations.

“Our new test is as accurate as the combined results of a standard blood test and ultrasound,” said Plebanski, a Senior National Health and Medical Research Council Fellow at RMIT.

“This is especially important for women in remote or disadvantaged communities, where under-resourced hospitals may not have access to complex and expensive equipment like ultrasound machines or MRI scanners.

“It also means patients with benign cysts identified through imaging could potentially be spared unnecessary surgeries.

“This study looked at women with advanced ovarian cancer, but we hope further research could explore the potential for adding this biomarker to routine diagnostic tests at earlier stages of the disease.”

The study used an immune marker for inflammation (IL-6) together with cancer markers to detect epithelial ovarian cancer in blood. Results were validated across two separate human trial cohorts.

“Ovarian cancer is the deadliest women’s cancer, a statistic that has not changed in 30 years,” Plebanski said.

“Every day in Australia, four women are diagnosed with ovarian cancer and three will die from the disease.

“Developing tests that are simpler and more practical may help get more women to hospital for treatment more effectively, with the hope that survival rates will improve.”

The research was a collaboration with Monash University, Universiti Kebangsaan Malaysia, University of Melbourne and Hudson Institute of Medical Research, with clinical trials held at the Royal Women’s Hospital and Epworth Healthcare in Melbourne.

The study was generously supported by the Women’s Cancer Fund, the Ovarian Cancer Research Foundation Inc., Australia, and the John Brunner estate.

Professor Magdalena Plebanski Professor Magdalena Plebanski.

Plebanski is the Director of the RMIT Biomedical and Health Innovation ECP, a cross-disciplinary research platform that works with industry to address areas of medical need and deliver interventions for health living.

She also leads the Translational Immunology and Nanotechnology (TIN) Research Program in the School of Health and Biomedical Sciences, focusing on the development of practical and affordable vaccines and treatments for complex diseases like malaria and cancer.

Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer’, with first author Associate Professor Nirmala Chandralega Kampan, is published in Scientific Reports (DOI: 10.1038/s41598-020-59009-z).


Story: Gosia Kaszubska

17 February 2020


17 February 2020


  • Research
  • Industry

Related News

aboriginal flag
torres strait flag

Acknowledgement of Country

RMIT University acknowledges the people of the Woi wurrung and Boon wurrung language groups of the eastern Kulin Nation on whose unceded lands we conduct the business of the University. RMIT University respectfully acknowledges their Ancestors and Elders, past and present. RMIT also acknowledges the Traditional Custodians and their Ancestors of the lands and waters across Australia where we conduct our business - Artwork 'Luwaytini' by Mark Cleaver, Palawa.